U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Regulatory Information
  3. Search for FDA Guidance Documents
  4. CVM GFI #260 - Type VII Veterinary Master File for Research and Development and Risk Reviews
  1. Search for FDA Guidance Documents

GUIDANCE DOCUMENT

CVM GFI #260 - Type VII Veterinary Master File for Research and Development and Risk Reviews January 2025

Download the Draft Guidance Document Read the Federal Register Notice
Draft

Not for implementation. Contains non-binding recommendations.

This guidance is being distributed for comment purposes only.

Submit Comments by

Submit Comments Online

Although you can comment on any guidance at any time (see 21 CFR 10.115(g)(5)), to ensure that the FDA considers your comment on a draft guidance before it begins work on the final version of the guidance, submit either online or written comments on the draft guidance before the close date.

If unable to submit comments online, please mail written comments to:

Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852

All written comments should be identified with this document's docket number: FDA-2024-D-5376

Docket Number:
FDA-2024-D-5376
Issued by:
Guidance Issuing Office
Center for Veterinary Medicine

A Type VII Veterinary Master File (VMF) is a file that can receive submissions to FDA’s Center for Veterinary Medicine (CVM) that may contain confidential data and information related to unique regulatory considerations such as research and development of animal cells, tissues, and cell- and tissue-based products (ACTPs), intentional genomic alterations (IGAs) in animals, gene therapy, or a risk review for an ACTP or IGA in an animal, where the information submitted is generally not intended to support product approval.  

The use of a Type VII VMF is appropriate for research and development of ACTPs, gene therapies, and IGAs in animals, and for risk review of ACTPs and IGAs in animals because, for these types of novel products and rapidly evolving technologies, there may be unique regulatory considerations, concerning different types of issues, that may call for a developer’s interactions with CVM at an earlier stage than would normally take place with traditional products that CVM regulates.  As described in the guidance, developers should open a Type VII VMF to cover these interactions with CVM.  The scope of this guidance is limited to the use of Type VII VMFs for research and development and risk review requests.  There are other uses of Type VII VMFs, but they are not addressed in this guidance.

The benefits of a Type VII VMF include:  (1) confidential exchange of information with FDA that is not subject to user fees, (2) an opportunity for increased communication with FDA during early stages of product development, and (3) a process for reporting research studies outside of an investigational file.

Questions?

Contact Point
Lynne Boxer
Center for Veterinary Medicine
Food and Drug Administration
7500 Standish Place
Rockville, MD 20855
Lynne.Boxer@fda.hhs.gov
240-402-0611
Back to Top